Tvardi Posts Q2 Loss, Picks Ulcerative Colitis for Lead STAT3 Drug
TVRD sits 21% above its 52-week low of $1.5 on light trading volume (0.1× avg).
Summary
Tvardi reported Q2 2026 results with a net loss of $6.5 million, down from net income of $4.2 million a year ago due to a prior-year non-cash gain. Cash fell to $15.8 million from $30.8 million at year-end, and the company continues to face a going concern warning. The key development is the selection of ulcerative colitis as the first indication for its next-generation STAT3 inhibitor TTI-109, supported by healthy volunteer data showing target engagement and immune cell modulation. A KOL webinar on August 19 will detail the UC opportunity, with TTI-101 HCC topline data expected in Q4 2026 and a TTI-109 UC trial planned for 2027 pending funding.
At the time of this announcement, TVRD was trading at $1.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.6M. The 52-week trading range was $1.50 to $43.65. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.